Psychological Medicine
May 4, 2026
Kristine Rømer Thomsen, B. Thylstrup, Morten Hesse et al.
Abstract Background In recent decades, the potency of cannabis resin increased globally, raising concerns, as higher potency has been associated with increased risk of psychiatric harms at the individual level. The aim here was to examine whether changes over time in the potency of seized cannabis resin samples were associated with psychiatric harms at the population level. Methods Data on...
American Journal of Preventive Medicine
May 4, 2026
Kevin H. Yang, Nora Satybaldiyeva, Wayne Kepner et al.
1 citation
IntroductionMicrodosing involves consuming low doses of psychoactive substances, typically between 1/5th and 1/20th of a recreational dose. Despite increasing public attention to cannabis and psychedelics amid evolving drug policies, epidemiologic data on microdosing remain limited.MethodsA cross-sectional, web-based survey (Characterizing the Epidemiology of Cannabidiol Use Survey) of 1,523...
Clinical Therapeutics
May 1, 2026
D. Valenti, Holly Kailher
PURPOSE Cannabis remains one of the most commonly used psychoactive substances among adolescents, with increasing prevalence of daily use during formative neurodevelopmental years. This preliminary study looks at changes in low spatial frequency contrast sensitivity perception using frequency doubling virtual reality technology (IMMAD-FDT). Early initiation of cannabis use-particularly before...
International Journal of Psychiatry Research
May 1, 2026
HH Ratobimanankasina, HA Razakandrainy, JDC Rasolonjatovo et al.
Background: Comorbidity between schizophrenia and cannabis use is associated with greater clinical complexity, behavioural dyscontrol, repeated admissions, and major social consequences. Published hospital data from Madagascar remain limited. Aim: To describe the epidemiological and clinical profile of patients with schizophrenia associated with reported cannabis use in the Psychiatry...
JAMA Internal Medicine
May 1, 2026
Devan Kansagara, Garth E Terry, Chelsea K Ayers et al.
Cannabis use is common among those with mental health conditions, and many people report using cannabis to manage mental health symptoms. It is important for clinicians to understand the lack of clear benefits of cannabis for mental health conditions and the potential for substantial adverse effects. Overall, the potential benefits of cannabis for mental health conditions remain poorly studied....
Early Intervention in Psychiatry
May 1, 2026
Ilaria Domenicano, Alice Onofrio, Domenico De Donatis et al.
ABSTRACT Aim This study aimed to investigate the association between cannabis use prior to enrollment in a First Episode Psychosis (FEP) program and prognosis, including severity of psychiatric symptoms, type of antipsychotic treatment prescribed, and clinical recovery. Methods A longitudinal cohort study was conducted on patients aged 18–35 diagnosed with affective and non‐affective psychosis...
Nature Mental Health
May 1, 2026
Daniel Bello, Sophia H. Blyth, Rachel A Rabin et al.
Cannabis and tobacco use are highly prevalent among people with psychosis and are associated with medical comorbidities and poor prognosis. Concurrent use of cannabis and tobacco (‘co-use’) is rising in the general population, but has not been studied in psychosis. Given the devastating consequences of cannabis and tobacco use, it is critical to understand how their co-use affects psychiatric...
European Journal of Pain
May 1, 2026
Michael M Morgan, Christa M. Hickey
Many people use cannabis to self-medicate for pain. Little is known about the impact of pain on tolerance and spontaneous withdrawal to delta-9-tetrahydrocannabinal (THC), the primary psychoactive compound in cannabis. Our previous research with the opioid morphine suggests persistent pain will increase the magnitude and duration of THC withdrawal. Male and female Sprague-Dawley rats were...
Psychopharmacology
May 1, 2026
Catherine F Moore, Elise M Weerts
Animal models of cannabinoid self-administration are critical for advancing our understanding of the neurobiology of cannabis use and for developing medications for Cannabis Use Disorder. Use of vapor inhalation models have translational relevance, as the majority of humans who use cannabis do so by inhalation (e.g., smoking, vaporization). Adult male and female Sprague Dawley rats (N = 96,...
JAMA Network Open
May 1, 2026
C Austin Zamarripa, Spencer Lin, Mckenna Klausner et al.
Simultaneous cannabis and alcohol use (co-use) is a public safety concern. Controlled data on the effects of co-ingestion of oral cannabis products (edibles) with alcohol are lacking, despite an increased prevalence of this behavior. To evaluate the individual and interactive effects of cannabis edibles and alcohol on simulated driving and subjective and objective impairment measures. This...